Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.
de Jong PH, Hazes JM, van Zeben D, van der Lubbe PA, de Jager MH, de Sonnaville PB, Luime JJ, Weel AE. de Jong PH, et al. Among authors: van der lubbe pa, van zeben d. Rheumatology (Oxford). 2012 Jul;51(7):1269-77. doi: 10.1093/rheumatology/kes008. Epub 2012 Feb 29. Rheumatology (Oxford). 2012. PMID: 22378716 Clinical Trial.
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, van Groenendael JH, Hazes JM, Breedveld FC, Allaart CF, Dijkmans BA. van der Kooij SM, et al. Among authors: van groenendael jh, van zeben d. Ann Rheum Dis. 2007 Oct;66(10):1356-62. doi: 10.1136/ard.2006.066662. Epub 2007 Feb 9. Ann Rheum Dis. 2007. PMID: 17293364 Free PMC article. Clinical Trial.
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE. de Jong PH, et al. Among authors: van zeben d. Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. doi: 10.1093/rheumatology/kew321. Epub 2016 Aug 30. Rheumatology (Oxford). 2016. PMID: 27581208 Clinical Trial.
44 results